EMA Refused: Nouryant (Istradefylline) — Kyowa Kirin Holdings B.V.

View source ↗

Summary

The EMA refused approval for Nouryant (istradefylline) for Parkinson's disease from Kyowa Kirin Holdings B.V.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Nouryant (istradefylline)

Snippet

Status: Refused. Therapeutic area: Parkinson Disease. MAH: Kyowa Kirin Holdings B.V.. Decision date: 22/07/2021